PCSK9 and diabetes mellitus: For the statin-intolerant patients and those requiring essential reductions in LDL-C to achieve their goals, new therapies, including PCSK9 inhibitors remain promising drugs. In BP research, AHA/ACC 2015 guidelines recommended a target for BP below 140/90 mmHg in stable or unstable CAD patients and below 150/90 mmHg in patients older than 80 years of age, however the recent results of the SPRINT trial have suggested that there might be significant benefits, taking into account CV risk, for hypertensive patients over 50 without diabetes and BP levels <120/80.